Tecan Group
Market Cap
CHF4.8b
Last Updated
2020/11/23 22:12 UTC
Data Sources
Company Financials +
Executive Summary
Tecan Group Ltd. provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. More Details
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Tecan Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TECN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TECN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
Market Performance
7 Day Return
0.9%
TECN
-3.6%
CH Life Sciences
0.05%
CH Market
1 Year Return
59.4%
TECN
73.6%
CH Life Sciences
1.0%
CH Market
Return vs Industry: TECN underperformed the Swiss Life Sciences industry which returned 73.6% over the past year.
Return vs Market: TECN exceeded the Swiss Market which returned 1% over the past year.
Shareholder returns
| TECN | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.9% | -3.6% | 0.05% |
| 30 Day | -5.8% | -1.5% | 4.0% |
| 90 Day | -4.9% | 1.8% | 1.6% |
| 1 Year | 60.7%59.4% | 74.5%73.6% | 4.5%1.0% |
| 3 Year | 109.5%104.0% | 132.6%127.2% | 18.6%4.0% |
| 5 Year | 186.0%172.1% | 252.3%229.5% | 36.3%13.8% |
Long-Term Price Volatility Vs. Market
How volatile is Tecan Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Tecan Group's (VTX:TECN) Earnings Are Growing But Is There More To The Story?3 weeks ago | Simply Wall St
Is Now The Time To Put Tecan Group (VTX:TECN) On Your Watchlist?1 month ago | Simply Wall St
Tecan Group (VTX:TECN) Shareholders Have Enjoyed An Impressive 240% Share Price GainValuation
Is Tecan Group undervalued compared to its fair value and its price relative to the market?
58.69x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TECN (CHF414.2) is trading above our estimate of fair value (CHF238.88)
Significantly Below Fair Value: TECN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TECN is good value based on its PE Ratio (58.7x) compared to the XE Life Sciences industry average (58.9x).
PE vs Market: TECN is poor value based on its PE Ratio (58.7x) compared to the Swiss market (22.7x).
Price to Earnings Growth Ratio
PEG Ratio: TECN is poor value based on its PEG Ratio (4.5x)
Price to Book Ratio
PB vs Industry: TECN is overvalued based on its PB Ratio (7.3x) compared to the XE Life Sciences industry average (5.1x).
Next Steps
Future Growth
How is Tecan Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
13.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECN's forecast earnings growth (13% per year) is above the savings rate (-0.2%).
Earnings vs Market: TECN's earnings (13% per year) are forecast to grow faster than the Swiss market (13% per year).
High Growth Earnings: TECN's earnings are forecast to grow, but not significantly.
Revenue vs Market: TECN's revenue (8.3% per year) is forecast to grow faster than the Swiss market (4.7% per year).
High Growth Revenue: TECN's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TECN's Return on Equity is forecast to be low in 3 years time (13.7%).
Next Steps
Past Performance
How has Tecan Group performed over the past 5 years?
9.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TECN has high quality earnings.
Growing Profit Margin: TECN's current net profit margins (12.9%) are higher than last year (10.8%).
Past Earnings Growth Analysis
Earnings Trend: TECN's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: TECN's earnings growth over the past year (25.4%) exceeds its 5-year average (9% per year).
Earnings vs Industry: TECN earnings growth over the past year (25.4%) underperformed the Life Sciences industry 30.1%.
Return on Equity
High ROE: TECN's Return on Equity (12.4%) is considered low.
Next Steps
Financial Health
How is Tecan Group's financial position?
Financial Position Analysis
Short Term Liabilities: TECN's short term assets (CHF647.8M) exceed its short term liabilities (CHF173.6M).
Long Term Liabilities: TECN's short term assets (CHF647.8M) exceed its long term liabilities (CHF119.0M).
Debt to Equity History and Analysis
Debt Level: TECN's debt to equity ratio (0.8%) is considered satisfactory.
Reducing Debt: TECN's debt to equity ratio has reduced from 1.5% to 0.8% over the past 5 years.
Debt Coverage: TECN's debt is well covered by operating cash flow (2544.6%).
Interest Coverage: TECN's interest payments on its debt are well covered by EBIT (116.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Tecan Group current dividend yield, its reliability and sustainability?
0.53%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TECN's dividend (0.53%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.88%).
High Dividend: TECN's dividend (0.53%) is low compared to the top 25% of dividend payers in the Swiss market (3.69%).
Stability and Growth of Payments
Stable Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TECN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TECN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Achim von Leoprechting (52 yo)
1.58yrs
Tenure
CHF2,473,158
Compensation
Dr. Achim Von Leoprechting, Ph.D., has been Chief Executive Officer of Tecan Group Ltd., since April 1, 2019. He has been Head of the Partnering Business division at Tecan Group Ltd. since October 1, 2013 ...
CEO Compensation Analysis
Compensation vs Market: Achim's total compensation ($USD2.71M) is about average for companies of similar size in the Swiss market ($USD2.22M).
Compensation vs Earnings: Insufficient data to compare Achim's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of the Partnering Business Division | 1.58yrs | CHF2.47m | 0.047% CHF 2.3m | |
| Chief Financial Officer & Member of Management Board | 0.67yr | no data | no data | |
| Executive VP | 8.83yrs | no data | 0.033% CHF 1.6m | |
| Executive VP | 7.42yrs | no data | 0.039% CHF 1.9m | |
| Executive VP | 6.33yrs | no data | 0.038% CHF 1.8m | |
| Head of Corporate Development | 2.92yrs | no data | 0.021% CHF 1.0m | |
| CTO, Executive VP | 1.25yrs | no data | 0.0095% CHF 458.0k | |
| Executive VP | 0.83yr | no data | no data | |
| Chief People Officer & Member of the Management Board | 0.25yr | no data | no data | |
| Senior Vice President of Corporate Communications & Investor Relations | 5.83yrs | no data | no data | |
| President of Sales International | no data | no data | no data | |
| Head of Tecan Asia | no data | no data | no data |
2.3yrs
Average Tenure
50yo
Average Age
Experienced Management: TECN's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 2.5yrs | CHF136.00k | 0.0016% CHF 79.1k | |
| Independent Director | 9.58yrs | CHF136.00k | 0.023% CHF 1.1m | |
| Independent Vice Chairman | 13.58yrs | CHF163.00k | 0.14% CHF 6.8m | |
| Director | 5.58yrs | CHF126.00k | 0.0039% CHF 190.1k | |
| Chairman | 2.5yrs | CHF338.00k | 0.0041% CHF 198.3k | |
| Independent Director | 8.58yrs | CHF140.00k | no data | |
| Independent Director | 7.58yrs | CHF147.00k | 0.012% CHF 574.3k |
7.6yrs
Average Tenure
61yo
Average Age
Experienced Board: TECN's board of directors are considered experienced (7.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Tecan Group Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Tecan Group Ltd.
- Ticker: TECN
- Exchange: SWX
- Founded: 1980
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF4.826b
- Shares outstanding: 11.95m
- Website: https://www.tecan.com
Number of Employees
Location
- Tecan Group Ltd.
- Seestrasse 103
- Männedorf
- Zurich
- 8708
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TEN | DB (Deutsche Boerse AG) | Yes | Registered Shares | DE | EUR | Jun 1999 |
| TECN | SWX (SIX Swiss Exchange) | Yes | Registered Shares | CH | CHF | Jun 1999 |
| TCHB.F | OTCPK (Pink Sheets LLC) | Yes | Registered Shares | US | USD | Jun 1999 |
| 0QLN | LSE (London Stock Exchange) | Yes | Registered Shares | GB | CHF | Jun 1999 |
| TECN N | BMV (Bolsa Mexicana de Valores) | Yes | Registered Shares | MX | MXN | Jun 1999 |
Biography
Tecan Group Ltd. provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/23 22:12 |
| End of Day Share Price | 2020/11/20 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.